BRPI1013085A2 - imunoglobulinas anti-cd52 humana - Google Patents

imunoglobulinas anti-cd52 humana Download PDF

Info

Publication number
BRPI1013085A2
BRPI1013085A2 BRPI1013085-3A BRPI1013085A BRPI1013085A2 BR PI1013085 A2 BRPI1013085 A2 BR PI1013085A2 BR PI1013085 A BRPI1013085 A BR PI1013085A BR PI1013085 A2 BRPI1013085 A2 BR PI1013085A2
Authority
BR
Brazil
Prior art keywords
seq
nos
light chain
heavy chain
antibody
Prior art date
Application number
BRPI1013085-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Bruce L. Roberts
Srinivas Shankara
William Harold Brondyk
William M. Siders
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1013085(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of BRPI1013085A2 publication Critical patent/BRPI1013085A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
BRPI1013085-3A 2009-05-13 2010-05-13 imunoglobulinas anti-cd52 humana BRPI1013085A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17783709P 2009-05-13 2009-05-13
US61/177,837 2009-05-13
PCT/US2010/034704 WO2010132659A2 (en) 2009-05-13 2010-05-13 Anti-human cd52 immunoglobulins

Publications (1)

Publication Number Publication Date
BRPI1013085A2 true BRPI1013085A2 (pt) 2020-11-03

Family

ID=43085579

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013085-3A BRPI1013085A2 (pt) 2009-05-13 2010-05-13 imunoglobulinas anti-cd52 humana

Country Status (19)

Country Link
US (5) US8617554B2 (en:Method)
EP (3) EP2429582A4 (en:Method)
JP (4) JP5894912B2 (en:Method)
KR (5) KR20160103160A (en:Method)
CN (3) CN102459628A (en:Method)
AR (1) AR076770A1 (en:Method)
AU (1) AU2010249003B2 (en:Method)
BR (1) BRPI1013085A2 (en:Method)
CA (2) CA2761800C (en:Method)
HK (2) HK1222682A1 (en:Method)
IL (2) IL216141B (en:Method)
MX (1) MX2011012047A (en:Method)
MY (1) MY160126A (en:Method)
NZ (2) NZ621170A (en:Method)
RU (2) RU2603743C2 (en:Method)
SG (2) SG10201608169QA (en:Method)
TW (3) TWI614267B (en:Method)
WO (1) WO2010132659A2 (en:Method)
ZA (1) ZA201108077B (en:Method)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009131712A2 (en) 2008-04-25 2009-10-29 Duke University Medical Center Regulatory b cells and their uses
MX342907B (es) 2009-05-13 2016-10-17 Genzyme Corp * El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
US8617554B2 (en) * 2009-05-13 2013-12-31 Genzyme Corporation Anti-human CD52 immunoglobulins
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
JP6104794B2 (ja) * 2011-04-18 2017-03-29 国立大学法人 東京大学 抗ｉｔｍ２ａ抗体を用いる癌の診断および治療
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
JP6184965B2 (ja) 2011-10-28 2017-08-23 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
WO2013185165A1 (en) * 2012-06-14 2013-12-19 The Walter And Eliza Hall Institute Of Medical Research Cd-52 antibodies and their use in determining and enhancing an immune response in a subject
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
WO2014066271A1 (en) * 2012-10-22 2014-05-01 Becton, Dickinson And Company Non-b-lineage cells capable of producing antibody
CA2903817A1 (en) 2013-03-12 2014-10-09 Institute of Arthritis Research, LLC Immunologically active polypeptide
ES2766762T3 (es) 2013-03-13 2020-06-15 Prothena Biosciences Ltd Inmunoterapia contra Tau
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
KR102042174B1 (ko) 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
AU2014250940A1 (en) 2013-04-09 2015-10-22 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
KR102186363B1 (ko) * 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) * 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
JP2018521979A (ja) 2015-06-03 2018-08-09 ボストン バイオメディカル， インコーポレイテッド 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
CU24537B1 (es) 2016-05-02 2021-07-02 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
KR102506091B1 (ko) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 타우 면역요법
CN109415434B (zh) 2016-05-02 2022-12-30 普罗塞纳生物科学有限公司 识别tau的抗体
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018112407A1 (en) 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
CN110546167A (zh) 2017-04-21 2019-12-06 建新公司 以抗-cd52抗体治疗多发性硬化症
PE20200695A1 (es) * 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
JP2021511068A (ja) * 2017-12-20 2021-05-06 ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｅｎｔｒｉｎ−１に対する抗体、作製方法、及びその使用
WO2020132091A2 (en) * 2018-12-19 2020-06-25 Humabs Biomed Sa Antibodies that neutralize hepatitis b virus and uses thereof
EA202191736A1 (ru) 2018-12-20 2021-10-01 Вир Байотекнолоджи, Инк. Комбинированная терапия hbv
WO2020180819A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
CN109929835A (zh) * 2019-03-27 2019-06-25 中国人民解放军第四军医大学 一种鼠单克隆抗体功能轻链可变区基因的扩增方法
KR20250156861A (ko) 2019-05-21 2025-11-03 노파르티스 아게 Cd19 결합 분자 및 이의 용도
MX2021015670A (es) * 2019-07-02 2022-04-18 Telix Int Pty Ltd Anticuerpos contra caix con afinidad reducida por el receptor de fc neonatal.
CN115515984A (zh) * 2020-05-08 2022-12-23 亘喜生物科技（上海）有限公司 一种抗cd19抗体的抗体及其制备和应用
CA3199001A1 (en) * 2020-11-19 2022-05-27 Victor R. Cairns Flow cytometry attenuated reporter expression (flare) multiple reporter system and methods of use thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2025031965A1 (en) * 2023-08-04 2025-02-13 Cimeio Therapeutics Ag Discernible cell surface protein variants of cd52 for use in cell therapy

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0684377B2 (ja) 1986-04-17 1994-10-26 協和醗酵工業株式会社 新規化合物ｄｃ―８８ａ及びｄｃ―８９ａ１
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
ATE95068T1 (de) 1988-02-12 1993-10-15 British Tech Group Modifizierte antikoerper.
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9108056D0 (en) * 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
PT705833E (pt) 1994-04-22 2004-11-30 Kyowa Hakko Kogyo Kk Derivado de dc-89
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
DE69934967T2 (de) 1998-12-08 2007-12-06 Biovation Ltd. Verfahren zur verminderung der immunogenität von proteinen
EP1242401B1 (en) 1999-11-24 2006-12-27 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
BRPI0108923B8 (pt) 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) * 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
AU2003291281A1 (en) 2002-11-01 2004-06-07 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) * 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
JPWO2004087210A1 (ja) * 2003-03-31 2006-06-29 麒麟麦酒株式会社 抗ｃｄ５２抗体による調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
DK1694706T3 (da) 2003-11-01 2012-07-16 Merck Patent Gmbh Modificeret anti-CD52-antistof
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
EP1786836A2 (en) * 2004-09-02 2007-05-23 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
MX2007009545A (es) 2005-02-08 2008-03-11 Genzyme Corp Anticuerpos para tgfbeta.
CA2609480A1 (en) * 2005-05-24 2006-11-30 Avestha Gengraine Technologies Pvt Ltd. Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia
DK1888113T3 (da) 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
JP2009521909A (ja) * 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ＩＬ−６とＩＬ−６Ｒαの複合体のｇｐ１３０への結合を阻害する抗ＩＬ−６抗体
WO2007121233A1 (en) * 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
JP5872756B2 (ja) 2006-09-13 2016-03-01 アルカフロイ マネージメント ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト カンパス−１Ｈ（Ｃａｍｐａｔｈ−１Ｈ）による多発性硬化症（ＭＳ）治療
AU2008219681A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
CA2689408A1 (en) * 2007-06-22 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
US20120058082A1 (en) 2009-05-13 2012-03-08 Genzyme Corporation Methods and compositions for treatment
US8617554B2 (en) * 2009-05-13 2013-12-31 Genzyme Corporation Anti-human CD52 immunoglobulins
MX342907B (es) 2009-05-13 2016-10-17 Genzyme Corp * El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
ES2673323T3 (es) 2009-07-15 2018-06-21 Aimm Therapeutics B.V. Compuestos de unión específica a bacterias gram positivas
EP4219805B1 (en) 2010-07-16 2025-02-26 Adimab, LLC Antibody libraries
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
MX385679B (es) 2014-10-09 2025-03-18 Genzyme Corp Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
CN110546167A (zh) 2017-04-21 2019-12-06 建新公司 以抗-cd52抗体治疗多发性硬化症

Also Published As

Publication number Publication date
KR20120111932A (ko) 2012-10-11
CA2939492C (en) 2019-03-19
CN102459628A (zh) 2012-05-16
CA2939492A1 (en) 2010-11-18
KR20160103160A (ko) 2016-08-31
TW201636367A (zh) 2016-10-16
IL216141B (en) 2018-11-29
CA2761800C (en) 2016-09-27
US11945874B2 (en) 2024-04-02
SG176060A1 (en) 2011-12-29
RU2011150516A (ru) 2013-06-20
CN104231084A (zh) 2014-12-24
US8617554B2 (en) 2013-12-31
HK1205152A1 (en) 2015-12-11
US20160208010A1 (en) 2016-07-21
JP5894912B2 (ja) 2016-03-30
MY160126A (en) 2017-02-28
IL262639A (en) 2018-12-31
IL216141A0 (en) 2012-01-31
TW201825115A (zh) 2018-07-16
JP2012526558A (ja) 2012-11-01
KR101537840B1 (ko) 2015-07-22
RU2603743C2 (ru) 2016-11-27
TWI614267B (zh) 2018-02-11
JP2016093194A (ja) 2016-05-26
EP2429582A4 (en) 2013-01-23
JP2018029624A (ja) 2018-03-01
AR076770A1 (es) 2011-07-06
EP3683317A3 (en) 2020-09-30
AU2010249003A1 (en) 2011-11-03
KR20140102764A (ko) 2014-08-22
ZA201108077B (en) 2013-01-30
EP3683317A2 (en) 2020-07-22
US20120100152A1 (en) 2012-04-26
NZ621170A (en) 2015-08-28
EP2998405B1 (en) 2019-12-11
MX2011012047A (es) 2011-12-14
CN110016081A (zh) 2019-07-16
US20140341910A1 (en) 2014-11-20
NZ596384A (en) 2014-03-28
CA2761800A1 (en) 2010-11-18
TW201043694A (en) 2010-12-16
HK1222682A1 (en) 2017-07-07
KR20160005143A (ko) 2016-01-13
KR20170113704A (ko) 2017-10-12
AU2010249003B2 (en) 2015-08-20
RU2016142225A (ru) 2018-12-18
EP2429582A2 (en) 2012-03-21
US20220010024A1 (en) 2022-01-13
JP2014195474A (ja) 2014-10-16
EP2998405A1 (en) 2016-03-23
TWI529247B (zh) 2016-04-11
WO2010132659A3 (en) 2011-01-06
US20200040091A1 (en) 2020-02-06
CN104231084B (zh) 2019-04-23
WO2010132659A2 (en) 2010-11-18
SG10201608169QA (en) 2016-11-29

Similar Documents

Publication Publication Date Title
US11945874B2 (en) Anti-human CD52 immunoglobulins
CN112969714A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
AU2017202364B2 (en) Anti-human CD52 immunoglobulins
CN119735683B (zh) 抗trem2抗体及其用途
HK40031934A (en) Anti-human cd52 immunoglobulins

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2602 DE 17/11/2020 POR TER SIDO INDEVIDA.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2601 DE 10-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]